Chemistry:MEDI7352
From HandWiki
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Legal status | |
| Legal status |
|
MEDI7352 is an experimental non-opioid analgesic drug that works as a bispecific monoclonal antibody against tumour necrosis factor (TNF) and nerve growth factor (NGF); it is developed by AstraZeneca for chronic pain.[1][2][3][4]
References
- ↑ "Late-stage pain pipeline refuses to swell" (in en). Evaluate.com. 26 April 2022. https://www.evaluate.com/vantage/articles/analysis/spotlight/late-stage-pain-pipeline-refuses-swell.
- ↑ Conaghan, Philip G.; Cook, Andrew D.; Hamilton, John A.; Tak, Paul P. (June 2019). "Therapeutic options for targeting inflammatory osteoarthritis pain" (in en). Nature Reviews Rheumatology 15 (6): 355–363. doi:10.1038/s41584-019-0221-y. ISSN 1759-4804. PMID 31068673. https://www.nature.com/articles/s41584-019-0221-y.
- ↑ Alcaraz, María José; Guillén, María Isabel; Ferrándiz, María Luisa (July 2019). "Emerging therapeutic agents in osteoarthritis". Biochemical Pharmacology 165: 4–16. doi:10.1016/j.bcp.2019.02.034. PMID 30826327.
- ↑ Zhao, Qi (April 2020). "Bispecific Antibodies for Autoimmune and Inflammatory Diseases: Clinical Progress to Date". BioDrugs 34 (2): 111–119. doi:10.1007/s40259-019-00400-2. PMID 31916225.
 |  |
